Search for content, post, videos

AstraZeneca completes acquisition of TeneoTwo

The pharma giant has completed the acquisition of TeneoTwo (announced July 5 2022), including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.

AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies.

An upfront payment of 100 million USD

AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of 100 million USD. Under the terms of the agreement, AstraZeneca will make additional contingent R&D-related milestone payments of up to 805 million USD and additional contingent commercial-related milestone payments of up to 360 million USD to TeneoTwo’s former equity holders.

This acquisition did not include the transfer of people or facilities.

TeneoTwo, Inc., is a majority owned subsidiary company of TBio, LLC, a limited liability company formed in Delaware, US.

Photo: AstraZeneca R&D